Evidence map›Paper›PMID 33790857›Full record

ReviewFrontiers in endocrinology2021

Dooming Phagocyte Responses: Inflammatory Effects of Endogenous Oxidized Phospholipids.

Marco Di Gioia, Ivan Zanoni

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Investigation of the Mechanism of Action ofMolecules (Basel, Switzerland) · 2023
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Marco Di GioiaDivision of Immunology, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States.
Ivan ZanoniDivision of Immunology, Harvard Medical School, Boston Children's Hospital, Boston, MA, United States.
Harvard University · US

Funding

Type III interferon Control of Mucosal ImmunityR01DK115217 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI Scott B Snapper, Ivan Zanoni · 2017 to 2026
$5.6M
Innate control of the inflammatory process during fungal infectionsR01AI121066 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI ZANONI, IVAN · 2016 to 2025
$4.8M
NIAID NIH HHS R01 AI121066NIDDK NIH HHS R01 DK115217
6 · The paper itself

Abstract

Endogenous oxidized phospholipids are produced during tissue stress and are responsible for sustaining inflammatory responses in immune as well as non-immune cells. Their local and systemic production and accumulation is associated with the etiology and progression of several inflammatory diseases, but the molecular mechanisms that underlie the biological activities of these oxidized phospholipids remain elusive. Increasing evidence highlights the ability of these stress mediators to modulate cellular metabolism and pro-inflammatory signaling in phagocytes, such as macrophages and dendritic cells, and to alter the activation and polarization of these cells. Because these immune cells serve a key role in maintaining tissue homeostasis and organ function, understanding how endogenous oxidized lipids reshape phagocyte biology and function is vital for designing clinical tools and interventions for preventing, slowing down, or resolving chronic inflammatory disorders that are driven by phagocyte dysfunction. Here, we discuss the metabolic and signaling processes elicited by endogenous oxidized lipids and outline new hypotheses and models to elucidate the impact of these lipids on phagocytes and inflammation.

Indexed as

AnimalsCOVID-19HumansInflammationOxidation-ReductionPhagocytesPhospholipidsPhospholipidsatherosclerosisCOVID-19immunometabolisminflammasomeinflammationlungoxidized phospholipidsoxPAPC

Identifiers

PMID33790857
PMCPMC8005915
OpenAlexW3139418052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.